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48 Poster Session Ienhancement to determine the role of contact, the effect on prolif-
eration and apoptosis, as well as possible molecular mechanisms.
Methods: CD34-selected or non-selected UCB cells were co-cul-
tured with MSC under serum-free conditions. CD451 and
CD341 cells were detected b flow-cytometry. Progenitor function
was determined by colony forming unit assay. Non-viable and early
apoptotic cell detection was based on 7-Amino-ActinomycinD/An-
nexin-V staining. Cell cycle analysis was based on propidium iodide
staining. Results: CD341 selected as well as non-selected UCB
cells had 2 to 5 fold enhancement of growth when cultured on
MSCs compared to expansion in cytokines alone. Over 90% of
the proliferative activities were contributed by the CD34-selected
cells. Progenitor cells expanded rapidly only during the first 7
days of co-culture but declined afterwards. The enhancement on
UCB expansion was maximized when the MSC layer was in direct
contact with the UCB cells. UCB cells co-cultured with MSC re-
sulted in 2- to 4-fold lower apoptotic cell fraction, andUCB cell-cy-
cling activities were not affected. Conclusions: The main
mecahnism of enhancement of CBU cultures on MSC co-cultures
appears to be due to rescue of cells from apoptosis during the initial
few days of culture rather than due to a direct effect on augmenting
proliferation. The molecules involved in this interaction aree being
investigated in our laboratory.125
STROMA FORMATION FROM FRESH AND CRYOPRESERVED MONONU-
CLEAR CELLS OBTAINED AT THE PRE AND POST-MOBILIZATION
PHASES FOR AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANS-
PLANTATION
Schimiegue, D.M.2, Silva, L.1, Dreyfuss, J.L.3, Zattar, K.C.2,
Nader, H.B.3, Borelli, P.4, Oliveira, J.S.R.2 1The University of Texas
MD Anderson Cancer Center, Houston, TX; 2University Federal of
Sao Paulo, Sao Paulo, Brazil; 3University Federal of Sao Paulo, Sao
Paulo, Brazil; 4University State of Sao Paulo, Sao Paulo, Brazil.
Background: Autologous hematopoeitic stem cell transplanta-
tion (auto-HSCT) comprises the manipulation of bone marrow
and peripheral blood HSC by cryopreservation and posterior thaw-
ing. These manipulations can cause cell damage, especially in pa-
tients submitted to aggressive induction remission chemotherapy,
radiation and auto-HSCT conditioning. Study Design and
Methods: Thirty-two bone marrow samples (22 patients and 10
controls) were collected at pre-mobilization phase and 27 (20 pa-
tients and 7 controls) at post-mobilization, respectively. Fresh or
cryopreserved mononuclear cells were cultured for eleven months
and had their confluency capacity analyzed. Results: In regard to
confluency achievement, there was no difference between fresh
and cryopreserved samples from pre-mobilization phase. Apart
from this, cells from 6 of the 11 (54%) fresh samples collected
from patients at pre-mobilization phase achieved $70% conflu-
ency. Cells from all (5 of 5, 100%) fresh control samples collected
at this phase and from 4 of the 5 (80%) cryopreserved, achieved
$70% confluency. Cells from 5 of the 10 (50%) fresh samples col-
lected from patients during the post-mobilization and 4 of the 10
(40%) cryopreserved samples reached$70% confluency. Consider-
ing the control group from this phase, cells from half (1 of 2) of the
fresh samples and from 1 of the 5 cryopreserved samples, achieved
$70% confluency. Conclusion: Stroma establishment from nor-
mal hematopoietic progenitors post mobilization is reduced when
compared to samples obtained from patients with hematologic ma-
lignancies, most probably due to higher sensitivity of healthy pro-
genitor cells to cryopreservation and thawing-induced damage.126
CO-TRANSPLANTATION OF MESENCHYMAL STEM CELLS AND HEMATO-
POIETIC STEM CELLS IN ß-THALASSEMIA PATIENTS
Ghavamzadeh, A., Valizadeh, N., Alimoghaddam, K., Karimi, A.,
Bahoush, G., Bashtar, M., Shamshiri, A.R., Jalili, M., Mosavi, A.S.,
Shahriari, Z., Basirpanah, S., Khalilvand, S., Chardouli, B.,Khatami, F. University of Tehran/Medical Sciences, Tehran, Islamic Re-
public of Iran.
Background: mesenchymal stromal cells are immunomodoula-
trory and may have important role in engraftement and GVHD/
HVGD. we studied co-transplantation of ex vivo expanded MSCs
andHSC.Patients andMethods: In this study, we coadministered
culture-expanded MSCs with HLA-identical sibling-matched
HSCs in b-thalassemia patients. Between Nowember 2006 and
February 2007, 10 ß-thalassemia patients were enrolled. Patients re-
ceived Cyclophosphamide-based or Fludarabine –based condition-
ing regimens and short course methotrexate and cyclosporine as
GVHD prophylaxis. On day 0, patients were given MSCs intrave-
nously (1.0–2.24  106/kg) 4 hours before infusion of either bone
marrow or peripheral blood stem cells. Outcomes of transplantation
compared between these patients with 50 matched - historical con-
trols group which were transplanted with HSCs in last years.
Matching criteria were included: recipients’ gender, source of
stem cell (bone marrow or peripheral blood), thalassemia group (in-
termediate or major), class of ß-thalassemia major (I, II, III) . Re-
sults: Chills and fever was only notable toxicity in MSC group.
The median time to achieve WBC engraftment $0.5  109/L
was 12.5 days (range 10–20 days) forMSC group and 12 days (range
6–52 days) in matched-historical control group (p-value 5 0.67).
Themedian time to achieve platelet engraftment$20 109/Lwas
18 days (range 12–30 days) forMSC group and 22 days (range 10–81
days) for comparison group (p-value 5 0.02). Incidence of acute
GVHDwas 80% and 76% inMSC and historical-matched group re-
spectively (p-value 5 1). 3-month overall survival rate was 90% and
91.7% in MSC and matched control group respectively (p-value 5
0.29). 100-day disease free survival rate was 80% and 87.8% in
MSC group and matched historical control group respectively (p-
value 5 0.27). Conclusion: In this study we demonstrated that co-
transplantation of HLA-identical sibling MSCs with HSCs is seems
to be safe. we can’t find statistical significant difference in acute
GVHD incidence, severity, OS, DFS, Median time to WBC recov-
ery between MSC group and compartion group.most probably ex-
plantation is small number of patients in study group.median time
to plt recovery was shorter in MSC group (p-value 5 0.02).
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MESENCHYMAL STEM CELLS EXERT DIFFERENTIAL EFFECTS ON ALLO-
ANTIGEN- AND VIRUS-SPECIFIC T CELLS
Karlsson, H.1,2, Samarasinghe, S.1, Ball, L.3, Sundberg, B.2,
Lankester, A.C.3, Dazzi, F.4, Rao, K.5, Veys, P.5, Le Blanc, K.2,
Ringden, O.2, Amrolia, P.J.1,5 1 Institute of Child Health, London,
United Kingdom; 2Karolinska Institute and Karolinska University Hos-
pital Huddinge, Stockholm, Sweden; 3Leiden University Medical Centre,
Leiden, Netherlands; 4 Imperial College School of Medicine, London,
United Kingdom; 5Great Ormond Street Hospital for Children, London,
United Kingdom.
Objectives: Mesenchymal stem cells (MSC) suppress alloanti-
gen-induced proliferation, interferon-g (IFN-g) production and
cytolytic killing in vitro and infusion of third-party MSC appears
a promising therapy for acute GVHD. However, little is known
about the specificity of immunosuppression by MSC and in partic-
ular the effect on cell-mediated immunity to infectious pathogens.
We have studied the effect of MSC on virus-specific T-cell re-
sponses. Results: Peripheral blood mononuclear cells (PBMC)
from 6 normal donors were stimulated for with autologous lympho-
blastoid cell lines (LCL) (EBV), pp65 peptides (CMV), an adenovi-
ral vector Ad5f35 (Ad) or allogeneic PBMC (Allo), in the presence
or absence of third-party MSC (MSC/PBMC ratio 1:10). MSC sig-
nificantly suppressed proliferation in response to Allo (mean 61%
suppression, p 5 0.003), but had less effect on the response to
EBV (mean 42% suppression, p 5 0.016) and no suppression of
the response to CMV or Ad. MSC had no effect on expansion of
EBV and CMV pentamer-specific T-cells after stimulation with
their cognate antigen. ELISPOT assays demonstrated that MSC
significantly inhibited IFN-g production in response to Allo
(mean SFC/105 cells 1125 6 274 without MSC, 263 6 49 with
MSC) and to a smaller extent to EBV (3181 6 548 vs 2147 6
387), but not to CMV (2535 6 374 vs 2532 6 311). Established
EBV-specific cytotoxic T-cells (EBV-CTL) from 5 donors were
Poster Session I 49stimulated with autologous LCL with or without MSC for 5 days.
The percentage of EBV-pentamer specific CTL was not affected
by the presence of MSC (mean 1.59% vs 1.52%). MSC did not in-
hibit IFN-g production by EBV-CTL (6039 6 1644 vs 5885 6
1608). Furthermore, cytolytic killing of LCL by EBV-CTL was
not suppressed by MSC (mean specific lysis 47 6 3.6% vs 52 6
4.7% at E:T ratio 30:1). Finally, we studied anti-CMV immunity
in 2 patiens who receivedMSC for acute GVHDof the gut evolving
into chronic GVHD, with a good transient response. PBMC from
these patients showed persistence of pp65-pentamer positive T-
cells and retained IFN-g response to CMV post MSC infusion
(mean SFC 91/105 PBMC pre-MSC, 113 at 2 weeks and 221 at 1
month post MSC infusion). Conclusion: MSC have little effect
on T-cell responses to CMV, EBV and Ad, which contrasts to their
strong immunosuppressive effects on alloreactive T-cells. These
data have major implications for immunotherapy of GVHD with
MSC and suggest that the effector functions of virus-specificT-cells
may be retained after MSC infusion.
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MAINTAININGTHE IN-VIVOHEMATOPOIETICNICHE IN-VITRO; ANOVEL
APPROACH TO STUDYING HEMATOPOEISIS IN BOTH A MURINE AND
A LARGE ANIMAL SYSTEM
Kraft, D.L., Smith, A., Weissman, I.L. Stanford University School of
Medicine, Stanford, CA; DRFV Foundation.
Introduction: INTRO: Hematopoietic Stem Cells (HSC) are
the most extensively characterized stem cell, yet understanding of
their niche, and the ability to maintain and expand HSCs in-vitro
remains a challenge. In vitro study of HSC has generally been lim-
ited to well-based cultures, or use of 3D structures, supplemented
with cytokines. As apposed to constructing an artificial niche, we
sought to examine whether the existent hematopoietic niche could
be maintained in-vitro and support HSC in-vitro, both in murine
long bones marrow fragments, & in perfused large animal vertebrae
and bone marrow cores. Methods: Femur and tibia from 3 month
old mice were harvested, and sectioned into 1/3rds ends removed to
facilitate perfusion of the bone marrow fragments (BMF). In addi-
tion, whole marrow ‘plugs’ were flushed from tibia. These were
then cultured in normal or low O2, in regularly changed media
1/- cytokines (Flt2, SCF, TPO). BMF were removed over time,
and analyzed by CFU assay and FACS for presence of HSC, &
transplanted into sublethally irradiated Ly5.2 recipients.
Large animal model: Fresh thoracic and lumbar vertebrae from
large juvenile swine were harvested and separated, then maintained
in culture as: non-perfused in media, syringe perfused by pump
from 0.5 to 1.5 ml/hr of media, or by surgically cannulated vertebral
artery and vein and maintained on a bioreactor. Vertebrae under-
went core biopsies every 1–2 days and were analyzed for viability
and by histology. Results:Murine BMF contained 35–72% viable
cells as measured by trypan blue exclusion at up to 14 days. In 4
to 11 day old BMF, a population of Slam1, KLS cells were detect-
able. In BMF transplanted recipients, donor derived cells were de-
tectable .4 months post transplant. Mean donor granulocyte
engraftment from BMF was 5.2 to 22.1%, compared to 19% from
an control BM cells, suggesting long-term engraftment was derived
from HSC maintained within cultured BMF. In porcine vertebral
bodies, non-perfused vertebrae had\10% viability by day 4 com-
pared to 20% viability if perfused by pump at .5 ml/hr or 49% via-
bility when perfused at .1 ml/hr. Histology revealed maintained
marrow structure and healthy appearing cells in marrow cores
from perfused vertebrae in contrast to unperfused marrow samples.
Conclusion:These results suggest that the intrinsicHSC niche can
be maintained in-vitro and further optimization of this approach
may provide a novel means to study murine and eventually human
HSC and niche in-vitro.
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ESTABLISHMENT OF BONE MARROW STROMA FROM PATIENTS AT PRE
AND POST-MOBILIZATION FOR AUTOLOGOUS PERIPHERAL BLOOD
STEM CELLS TRANSPLANTATION
Schimieguel, D.M.2, Silva, L.1, Dominato, J.A.3, Silva, M.R.R.4,
Nader, H.B.3, Borelli, P.5, Souza, M.K.2, Oliveira, J.S.R.2 1The Uni-versity of Texas MDAnderson Cancer Center, Houston, TX; 2University
Federal of Sao Paulo, Sao Paulo, Brazil; 3University Federal of Sao
Paulo, Sao Paulo, Brazil; 4University Federal of Sao Paulo, Sao Paulo,
Brazil; 5University State of Sao Paulo, Sao Paulo, Brazil.
Objective: Successful of autologous peripheral blood stem cell
transplantation relies on mobilization’s capacity of hematopoetic
progenitor cells frommarrow to blood stream.The aim of this study
was to evaluate the correlation between the velocity of establish-
ment and maintenance marrow’s stroma in vitro from mononuclear
cells and bone marrow biopsy data obtained before and after mobi-
lization treatment in hematologicmalignancies and controls.Mate-
rials and Methods: Were evaluated clinical data from 22 patients
and 10 healthy donors as controls regarding the velocity of estab-
lishment and maintenance of stroma through long-term bone mar-
row culture on semisolid medium and bone marrow
histopathological features. Results: Out of 32 samples harvested
at pre-mobilization, 21 (66%) achieve $70% confluency while 11
of 27 samples (34%) could do so after mobilization. At pre-mobili-
zation, 91% of samples that did not achieve confluency were from
patients. After mobilization, 9 (82%) and 2 (18%) samples from pa-
tients and controls reached confluency, respectively, indicating a re-
duction of stroma establishment potential, especially from controls
(p 5 0.03). We could not observe any difference between ‘‘good’’
and ‘‘poor’’ mobilizer in both times.Nevertheless, the velocity of es-
tablisment was faster from the controls than patients.Conclusions:
Patients with fibrotic or poor cellularity demonstrated lower capac-
ity of stroma’s establishing suggesting that damage might affect
most probably the marrow microenvironment than the hematopoi-
etic progenitors. However, a more reduction of stroma establish-
ment capacity disclosed in controls than patients after
mobilization might be due to a more intense mobilization in these
settings.HISTOCOMPATIBILITY/ALTERNATIVE
STEM CELL SOURCES130
DOUBLE UMBILICAL CORD BLOOD TRANSPLANTATIONWITH REDUCED
INTENSITY CONDITIONING AND SIROLIMUS-BASED GVHD PROPHY-
LAXIS
Cutler, C.1, Kao, G.1, Ho, V.1, Alyea, E.1, Koreth, J.1, Armand, P.1,
Dey, B.2, Spitzer, T.2, Soiffer, R.1, Antin, J.H.1, Ballen, K.2 1Dana-
Farber Cancer Institute, Boston, MA; 2Massachusetts General Hospital,
Boston, MA.
Single-unit umbilical cord blood transplantation (UCBT) in
adults is associated with high transplant-related mortality, largely
due to delayed engraftment and infection. Double UCBT
(DUCBT) is associated with faster engraftment, but also with
high rates of acute GVHD. We studied DUCBT using sirolimus
and tacrolimus to improve GVHD outcomes.
Methods: Conditioning consisted of fludarabine (30 mg/m2 
6), melphalan (100 mg/m2  1), and rabbit ATG (1.5 mg/kg  4).
UCB units were $4/6 HLA-A, B, DR allele-matched with each
other and the recipient, and contained a minimum combined dose
of 3.7  107 TNC/kg pre-cryopreservation. GVHD prophylaxis
was tacrolimus (5–10 ng/ml) and sirolimus (3–12 ng/ml). Results:
29 patients (median 49 years, range 19–67) with .100 day follow-
up are reported. Diagnoses include AML(8), NHL(7), HD(5),
MDS(4), CLL/PLL(2), ALL(1), MPD (1) and CML(1). The me-
dian total cell doses prior to cryopreservation were 5.2  107
TNC/kg (range 3.7–7.6  107) and 12.5  106 CD341 cells (range
1.5–29.0 106). Neutrophil engraftment occurred at amedian of 21
days (range 13–70) and platelet engraftment occurred at a median of
42 days (range 25–162) after DUCBT. Three subjects did not attain
platelet transfusion independence by day 100 and there were 3 late
graft failures. 3 patients developed Gr. II-IV acute GVHD (2 Gr. II
and 1 Gr. III, median 21 days). Acute GVHD was less frequent
when compared with a prior DUCBT cohort that received cyclo-
sporine and MMF as GVHD prophylaxis (10.3% vs. 36.9%, p 5
0.04). Only 2 patients developed chronic GVHD after DUCBT.
